Acute stroke: we have the treatments and we have the evidence – we need to use them by Quinn, Terence J et al.
Page 1 of 3
(page number not for citation purposes)
Available online http://ccforum.com/content/11/2/124
Abstract
Despite huge global burden, stroke disease has traditionally
received little attention in the general medical press. We review a
series of four acute stroke research articles published in a themed
issue of the Lancet. Claiborne-Johnston and coworkers presented
a scoring system to stratify risk of stroke following transient
ischaemic attack. Chalela and colleagues demonstrated that
magnetic resonance imaging is superior to computed tomography
in detecting acute ischaemic stroke and that fears of missing
intracranial haemorrhage are unfounded. The SITS-MOST (Safe
Implementation of Thrombolysis in Stroke - Monitoring Study)
group reported positive experience of translating acute stroke
thrombolysis trials into routine clinical practice in Europe, and the
PROSIT (Project on Stroke Services in Italy) group studied acute
effects of admission to a dedicated stroke unit. The message from
all of these reports is that evidence-based, successful manage-
ment of acute stroke is possible, and that investment in health
infrastructure and changing mind sets of health practitioners to
improve stroke care will deliver benefits.
The global burden of stroke is immense. Six million people
will die from stroke this year, with millions more left disabled.
Despite these alarming figures, we under-utilize proven acute
stroke treatments. As such, we welcome the recent stroke
themed issue of the Lancet. The research articles presented
in the journal mirror the stroke patient journey - from transient
ischaemic attack (TIA) [1] through acute stroke requiring
imaging [2] and therapy [3], to care within a dedicated stroke
ward [4].
We are all aware that TIA predicts stroke, but the magnitude
of risk has until recently been underestimated. In fact, stroke
risk during first week following TIA exceeds 30% in certain
groups [1]. Scoring systems have been developed to allow
risk stratification. Collaboration between UK and North
American centres produced the ABCD2 score [1]. (The
abbreviation ABCD2 is derived from the measures of age,
blood pressure, clinical signs, duration and diabetes, on
which the score is based.) This simple five-item instrument
identifies high (8.1%), medium (4.1%) and low (1%) 48-hour
stroke risk. The score was robustly developed and validated
in over 4,800 patients across diverse ethnic and socio-
economic groups.
Given the high initial risk for stroke, the best use of the score
may be to identify patients who require immediate in-patient
assessment. At the very least, by providing an assessment
framework it should improve detection of the highest risk
individuals but maybe improve diagnostic accuracy in
suspected TIA; at present approximately 50% of referrals to
diagnostic accuracy in TIA referrals is only 50% [5]. Although
the evidence base for hyper-early intervention in TIA is limited,
we know that prompt carotid endarterectomy is effective [6],
and acute stroke trials report reduced recurrence with
antiplatelet treatment [7]. We assume that early initiation of
secondary prevention in TIA will have similar effects, but we
await the results of ongoing trials to address this definitively.
We should treat stroke with at least the same urgency as
myocardial infarction; in fact, the time window for intervention
is shorter. All patients with stroke symptoms require brain
imaging to assist in diagnosis and to exclude treatable stroke
mimics. We have suspected for many years that magnetic
resonance imaging (MRI) is superior to computed
tomography (CT) in this regard; Chalela and colleagues [2]
have reported definitive proof. In a pragmatic trial of all
referrals to an acute stroke service, initial MRI had a
sensitivity of 83% in detecting acute ischaemic stroke; in
contrast, the sensitivity with CT was only 16%.
Traditionally, CT has been preferred because of perceived
superior sensitivity in detecting intracerebral haemorrhage
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(ICH), better (but by no means acceptable) availability and
concerns regarding practicalities of emergency MRI scan-
ning. In their study, Chalela and coworkers [2] demonstrated
equal ability of MRI to detect ICH in a real-time acute setting.
A strong case can now be made for 24-hour access to MRI in
all stroke centres. This requires investment; we note with
pessimism that many UK centres still struggle to achieve
national targets of CT scanning within 24 hours of ictus [8].
Consider the following scenario. sing MRI, a diagnosis of
ischaemic stroke has been made for your patient. If this were
myocardial infarct, thrombolytic therapy - with a number
needed to treat of approximately 30 to avoid one death [9] -
would be instituted. Imagine if a similar treatment were
available for acute ischaemic stroke but that the number
needed to treat to reduce disability was only three. Such a
treatment is available. We have known for more than a
decade that intravenous recombinant tissue-plasminogen
activator (rt-PA) is effective if administered within 3 hours of
stroke onset [10] and a recent meta-analysis has confirmed
efficacy [11] (Table 1).
There is of course a real and important risk for ICH with rt-PA.
As such it was a condition of the European licence that a
comprehensive monitoring study be performed (the SITS-
MOST [Safe Implementation of Thrombolysis in Stroke-
Monitoring Study]) [3]. This multicentre international study,
including 6,483 patients across 285 centres, confirmed a
high rate of good outcomes and allayed fears of frequent ICH
(Table 1).
The SITS-MOST population and definition of haemorrhage
demand some consideration. Only patients treated within the
strict terms of the European licence were studied, and so
patients with any of the following were excluded: age greater
than 80 years, severe stroke, anticoagulation, history of
diabetes and previous stroke. A substantial number of
patients treated with rt-PA do not satisfy these criteria, and
similar data on their outcomes would be of value. Sympto-
matic ICH was defined as haemorrhage involving 30% or
more of infarct volume with objective clinical deterioration [3].
Although this is a different definition to that used in the
original trials, it is arguably more meaningful. Previous
definitions of symptomatic ICH included patients with minor
bleeds or no measurable neurological sequelea. However,
even these generously defined events were less common in
routine practice than in the previous trials (Table 1).
An important finding in SITS-MOST [3] is that outcomes
were similar regardless of the experience of the centre
(although all were designated acute stroke centres), implying
that thrombolytic therapy should now be more widely used.
There is a long way to go; currently fewer than 5% of eligible
patients in Europe receive thrombolytic therapy.
All stroke patients, whether they are treated with rt-PA or not,
should be offered a further evidence-based intervention,
namely specialist stroke unit admission. A systematic review
has demonstrated consistent survival advantages of stroke
units in addition to their rehabilitation role [12]. To date,
studies provide little guidance on timing of admission and
long-term benefits. The PROSIT (Project on Stroke Services
in Italy) [4] observational study goes some way to addressing
this shortfall. Acute (within 48 hours) admission to a dedica-
ted stroke unit was associated with improved survival and
functional outcome; benefits persisted at long-term follow up.
In the PROSIT study [4] a loose definition of stroke unit care
was used. In extensive subgroup analysis, no single element
of stroke unit care was convincingly linked to improved
outcomes. The study was underpowered to address this
issue, but it remains likely that a stroke unit is ‘greater than
the sum of its parts’, with the individual components of care
working synergistically. Our limited understanding of why
stroke units work should not defer us from making use of this
evidence-based intervention. The number of hospitals in
PROSIT that offered dedicated stroke unit care is
disappointing (30 out of 260 hospitals) and emphasizes how
much further we have to go to improve stroke patient care in
Europe. Surprisingly, patients admitted to centres with stroke
units did better even if they were not admitted to the
specialist ward. Perhaps simply having an enthusiastic stroke
team within a centre has knock-on effects on other staff and
practices.
Table 1
Summary of outcomes from SITS-MOST, meta-analysis of previous rt-PA trials and placebo arm
Mortality  Independence  Symptomatic ICH  Symptomatic ICH 
(at 3/12) (at 3/12) (per SITS-MOST)a (per previous trials)b
Trials 17.3% 49% N/A 8.6%
SITS-MOST 11.3% 54.8% 1.7% 7.3%
Placebo 18.4% 30.2% N/A 1.9%
aBleed large enough to cause symptoms and accompanying neurological deterioration. bAny bleed with any alteration in neurological status,
regardless of severity. rt-PA, recombinant tissue-plasminogen activator; SITS-MOST, Safe Implementation of Thrombolysis in Stroke Monitoring
Study.Page 3 of 3
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A theme across all of the reports in this Lancet collection is
that evidence-based effective management of acute stroke is
possible but implementation will require changes in attitudes
and infrastructures. Our challenge is to promote utilization of
proven therapies while developing novel ones. We encourage
future generations of enthusiasts to help us take on this
challenge.
Competing interests
The authors declare no relevant competing interests in
relation to this work. KRL is a named author on the SITS-
MOST paper, and chaired the independent data monitoring
committees for the ECASS III and DIAS trials of thrombolysis
in stroke.
References
1. Johnston SC, Rothwell PF, Nguyen-huynh MN, Giles MF, Elkins
JS, Bernstein AL, Sidney S: Validation and refinement of scores
to predict very early stroke risk after transient ischaemic
attack. Lancet 2007, 369:283-292.
2. Chalela JA, Kidwell CS, Nentwich LM, Luby M, Butman JA,
Demchuk AM, Hill MD, Patronas N, Latour L, Warach S: Magnetic
resonance imaging and computed tomography in emergency
assessment of patients with suspected acute stroke: a
prospective comparison. Lancet 2007, 369:293-298.
3. Wahlgren N, Ahmed N, Davalos A, Ford GA, Grond M, Hacke W,
Hennerici MG, Kaste M, Kuelkens S, Larrue V, et al., for the SITS-
MOST investigators: Thrombolysis with alteplase for acute
ischaemic stroke in the Safe Implementation of Thrombolysis
in Stroke - Monitoring Study (SITS-MOST): an observational
study. Lancet 2007, 369:275-282.
4. Candelise L, Gattinoni M, Bersano A, Micieli G, Sterzi R, Morabito
A, on behalf of the PROSIT Study Group: Stroke-unit care for
acute stroke patients: an observational follow-up study.
Lancet 2007, 369:299-305.
5. Goldstein LB, Simel DL: Is this patient having a stroke? JAMA
2005, 293:2391-2402.
6. North American Symptomatic Carotid Endarterectomy Trial Col-
laborators:  Beneficial effect of carotid endarterectomy in
symptomatic patients with high-grade carotid stenosis. N
Engl J Med 1991, 325:445-453.
7. International Stroke Trial Collaborative Group: The international
stroke trial (IST): a randomised trial of aspirin, subcutaneous
heparin, both, or neither among 19435 patients with acute
ischaemic stroke. Lancet 1997, 349:1569-1581.
8. Royal College of Physicians: National Clinical Guidelines for
Stroke. London, UK: Royal College of Physicians; 2004.
9. Menon V, Harrington RA, Hochman JS, Cannon CP, Goodman
SD, Wilcox RG, Schunemann HJ, Ohman EM: Thrombolysis and
adjunctive therapy in acute myocardial infarction: The
Seventh ACCP Conference on Antithrombotic and Throm-
bolytic Therapy. Chest 2004, Suppl 3:549-575.
10. The National Institute of Neurological Disorders and Stroke rt-PA
study group: Tissue plasminogen activator for acute stroke. N
Engl J Med 1995, 333:1581-1587.
11. Hacke W, Donnan G, Fieschi C, Kaste M, von Kummer R, Broder-
ick JP, Brott T, Frankel M, Grotta JC, Haley EC Jr, et al.: Associa-
tion of outcome with early stroke treatment: Pooled analysis
of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet
2004, 363:768-744.
12. Stroke Unit Trialist’ Collaboration: Organised inpatient (stroke
unit) care for stroke (Cochrane Review). Cochrane Database
Syst Rev 2002, 1:CD000197.
Available online http://ccforum.com/content/11/2/124